NEWS

Dr Jack Resneck Jr commented: “Previously, the Declaration of Helsinki addressed WMA members and constituents. The new version of the Declaration says that as physicians, it’s part of our moral obligation to ensure that our patients and the participants in research are respected and treated with dignity,”

The vaccine, known as BNT116 is designed to target non-small cell lung cancer (NSCLC), and the Phase I trial is taking place in the UK, US, Germany, Spain, and Türkiye, among others,

An important medical ethics scandal in U.S. history and a landmark in clinical studies "Tuskegee Syphilis Study" was revealed by Peter Buxton who was a Public Health Service Employee at that time.

This report provides information about FDA-registered drug manufacturers2 and the quality of the U.S. drugs supply, including biological products regulated by CDER.

FDA’s Center for Drug Evaluation and Research (CDER) published the 2023 Office of New Drugs (OND) Annual Report, which lists the office’s major achievements of 2023 to include notable drug approvals, guidances, publications, participation in meetings, workshops, webinars, conferences, and more.  The report highlights innovations in drug design and progression in drug development as well as OND’s collaborations throughout FDA and with external stakeholders to address new challenges in drug deve

The FDA has published new draft guidance on informed consent. By consulting with patient advocacy groups and potential patients to provide more information on the clinical trial and to use digital technologies and visual resources are among the new guides..

Turkish Clinical Research Association will be organizing the 6th National Clinical Research Congress in Istanbul between 28-29 November..

The 5th International Conference on Clinical Trials will be held between 20-21 May in Budapest, Hungary

The U.S. Food and Drug Administration inspection in July at Lilly’s Branchburg, New Jersey, plant detected eight separate deficiencies.

The last version was issued in 2013. The revised version is open to public consultation and waiting for the feedback till 7 February 2024.